Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Ordinary Shares, NIS 1.80 par value per share
-
Shares outstanding
-
5.59M
-
Number of holders
-
13
-
Total 13F shares, excl. options
-
72.8K
-
Shares change
-
-3.16K
-
Total reported value, excl. options
-
$102K
-
Value change
-
-$18.5K
-
Number of buys
-
3
-
Number of sells
-
-7
-
Price
-
$1.38
Significant Holders of Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) as of Q3 2025
17 filings reported holding GLMD - Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share as of Q3 2025.
Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) has 13 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 72.8K shares
of 5.59M outstanding shares and own 1.3% of the company stock.
Largest 10 shareholders include CITADEL ADVISORS LLC (50.5K shares), TWO SIGMA INVESTMENTS, LP (21.2K shares), UBS Group AG (963 shares), MORGAN STANLEY (98 shares), Wealthspire Advisors, LLC (21 shares), SBI Securities Co., Ltd. (16 shares), Federation des caisses Desjardins du Quebec (14 shares), WELLS FARGO & COMPANY/MN (9 shares), OSAIC HOLDINGS, INC. (5 shares), and TD Waterhouse Canada Inc. (2 shares).
This table shows the top 13 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.